Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met-overexpressing (OE) advanced non-small cell lung cancer (NSCLC).
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 June 2022, vol.40, (Summary Text)
- Publication Type: Conference Paper / Summary Text
- Volume: 40
- Country: ELECTR NETWORK
- Trakya University Affiliated: Yes